Baseline characteristics of 2223 AML patients who underwent allogeneic HCT from 2002-2006
| Variable . | MRD . | 8/8 MUD . | 7/8 MUD . | P* . |
|---|---|---|---|---|
| Size, n | 624 | 1193 | 406 | |
| Centers, n | 62 | 99 | 84 | |
| Median age, y (range) | 52 (21-76) | 51 (21-75) | 48 (21-75) | < .001‡ |
| Age group, y, n (%) | < .001 | |||
| 20-29 | 54 (9) | 146 (12) | 67 (17) | |
| 30-39 | 74 (12) | 142 (12) | 70 (17) | |
| 40-49 | 165 (26) | 308 (26) | 93 (23) | |
| 50-59 | 229 (37) | 372 (31) | 113 (28) | |
| ≥ 60 | 102 (16) | 225 (19) | 63 (16) | |
| Sex, n (%) | .04 | |||
| Male | 356 (57) | 618 (52) | 226 (56) | |
| Female | 265 (42) | 574 (48) | 180 (44) | |
| Missing | 3 (< 1) | 1 (< 1) | 0 | |
| KPS, n (%) | < .001 | |||
| ≥ 90 | 382 (61) | 700 (59) | 231 (57) | |
| < 90 | 214 (34) | 336 (28) | 129 (32) | |
| Missing | 28 (4) | 157 (13) | 46 (11) | |
| Race, n (%) | < .001 | |||
| White | 528 (85) | 1134 (95) | 359 (88) | |
| Black | 38 (6) | 21 (2) | 27 (7) | |
| Asian | 18 (3) | 12 (1) | 5 (1) | |
| Other—American Indian/Native Hawaiian | 23 (4) | 6 (1) | 4 (1) | |
| Missing | 17 (3) | 20 (2) | 11 (3) | |
| AML disease status at transplantation, n (%) | < .001 | |||
| Primary induction failure | 91 (15) | 204 (17) | 65 (16) | |
| CR1 | 337 (54) | 547 (46) | 150 (37) | |
| CR2 | 97 (16) | 261 (22) | 109 (27) | |
| First relapse | 80 (13) | 173 (15) | 79 (19) | |
| Missing | 19 (3) | 8 (1) | 3 (1) | |
| Cytogenetics, n (%) | < .001 | |||
| Unknown | 29 (5) | 75 (6) | 31 (8) | |
| Normal | 288 (46) | 403 (34) | 127 (31) | |
| Good | 34 (5) | 80 (7) | 27 (7) | |
| Intermediate | 88 (14) | 134 (11) | 56 (14) | |
| Poor | 158 (25) | 394 (33) | 135 (33) | |
| Tested–not evaluated metaphases | 10 (2) | 46 (4) | 7 (2) | |
| Not tested | 17 (3) | 61 (5) | 23 (6) | |
| WBC count at diagnosis, n (%) | .30 | |||
| < 7.6 × 109/L | 258 (41) | 550 (46) | 180 (44) | |
| > 7.6 × 109/L | 296 (47) | 515 (43) | 175 (43) | |
| Missing | 70 (11) | 128 (11) | 51 (13) | |
| Therapy-related AML, n (%) | < .001 | |||
| No | 572 (92) | 1121 (94) | 378 (93) | |
| Yes | 35 (6) | 72 (6) | 25 (6) | |
| Missing | 17 (3) | 0 | 3 (1) | |
| Preexisting MDS, n (%) | < .001 | |||
| No | 426 (68) | 879 (74) | 309 (76) | |
| Yes | 130 (21) | 313 (26) | 95 (23) | |
| Missing | 68 (11) | 1 (< 1) | 2 (< 1) | |
| Extramedullary disease, n (%) | < .001 | |||
| No | 570 (91) | 1122 (94) | 387 (95) | |
| Yes | 39 (6) | 68 (6) | 16 (4) | |
| Missing | 15 (2) | 3 (< 1) | 3 (1) | |
| Median interval between diagnosis and transplantation, mo (range) | 5 (1-142) | 6 (1-133) | 7 (1-114) | |
| Median interval from CR1 to transplantation for patients transplanted in CR1, mo (range) | 3 (1-25) | 3 (1-24) | 4 (1-14) | |
| Median CR1 duration (only patients transplanted in CR2), mo (range) | 10 (1-53) | 11 (1-110) | 11 (1-100) | |
| Median donor age, y (range) | 50 (7-85) | 34 (19-61) | 37 (19-60) | < .001‡ |
| Donor age group, y, n (%) | < .001 | |||
| < 20 | 16 (3) | 14 (1) | 2 (< 1) | |
| 20-29 | 35 (6) | 406 (34) | 92 (23) | |
| 30-39 | 75 (12) | 427 (36) | 158 (39) | |
| 40-49 | 180 (29) | 273 (23) | 118 (29) | |
| 50-59 | 180 (29) | 71 (6) | 35 (9) | |
| > 60 | 131 (21) | 2 (< 1) | 0 | |
| Missing | 7 (1) | 0 | 1 (< 1) | |
| Sex match, n (%) | < .001 | |||
| M/M | 200 (32) | 436 (37) | 146 (36) | |
| M/F | 132 (21) | 369 (31) | 99 (24) | |
| F/M | 155 (25) | 182 (15) | 80 (20) | |
| F/F | 132 (21) | 205 (17) | 81 (20) | |
| Missing | 5 (1) | 1 (< 1) | 0 | |
| CMV match, n (%) | < .001 | |||
| +/+ | 258 (41) | 202 (17) | 96 (24) | |
| +/− | 71 (11) | 86 (7) | 37 (9) | |
| −/+ | 146 (23) | 499 (42) | 136 (33) | |
| −/− | 130 (21) | 325 (27) | 104 (26) | |
| Not tested/inconclusive | 19 (3) | 81 (7) | 33 (8) | |
| Conditioning regimen intensity, n (%) | .003 | |||
| Traditional ablative | 335 (54) | 547 (46) | 220 (54) | |
| Reduced intensity | 135 (22) | 336 (28) | 104 (26) | |
| Nonmyeloablative | 74 (12) | 148 (12) | 36 (9) | |
| Nontraditional ablative† | 80 (13) | 162 (14) | 45 (11) | |
| Missing | 0 | 0 | 1 (< 1) | |
| Stem cell source, n (%) | < .001 | |||
| BM | 48 (8) | 328 (27) | 105 (26) | |
| Peripheral blood | 576 (92) | 865 (73) | 301 (74) | |
| GVHD prophylaxis, n (%) | < .001 | |||
| Missing | 3 (< 1) | 0 | 0 | |
| None | 14 (2) | 8 (1) | 4 (1) | |
| FK506 + MTX + other | 241 (39) | 578 (48) | 191 (47) | |
| FK506 + other | 104 (17) | 249 (21) | 79 (19) | |
| CsA + MTX + other | 124 (20) | 192 (16) | 87 (21) | |
| CsA + other | 125 (20) | 149 (12) | 39 (10) | |
| Other | 13 (2) | 17 (1) | 6 (1) | |
| Antithymocyte globulin, n (%) | < .001 | |||
| No | 565 (91) | 894 (75) | 306 (75) | |
| Yes | 59 (9) | 299 (25) | 100 (25) | |
| Year of transplantation, n (%) | ||||
| 2002 | 99 (16) | 124 (10) | 38 (9) | |
| 2003 | 89 (14) | 166 (14) | 69 (17) | |
| 2004 | 141 (23) | 275 (23) | 89 (22) | |
| 2005 | 157 (25) | 295 (25) | 106 (26) | |
| 2006 | 138 (22) | 333 (28) | 104 (26) | |
| Median follow-up of survivors, mo (range) | 57 (2-97) | 42 (6-89) | 45 (3-85) | |
| Total deaths, n | 397 | 773 | 275 |
| Variable . | MRD . | 8/8 MUD . | 7/8 MUD . | P* . |
|---|---|---|---|---|
| Size, n | 624 | 1193 | 406 | |
| Centers, n | 62 | 99 | 84 | |
| Median age, y (range) | 52 (21-76) | 51 (21-75) | 48 (21-75) | < .001‡ |
| Age group, y, n (%) | < .001 | |||
| 20-29 | 54 (9) | 146 (12) | 67 (17) | |
| 30-39 | 74 (12) | 142 (12) | 70 (17) | |
| 40-49 | 165 (26) | 308 (26) | 93 (23) | |
| 50-59 | 229 (37) | 372 (31) | 113 (28) | |
| ≥ 60 | 102 (16) | 225 (19) | 63 (16) | |
| Sex, n (%) | .04 | |||
| Male | 356 (57) | 618 (52) | 226 (56) | |
| Female | 265 (42) | 574 (48) | 180 (44) | |
| Missing | 3 (< 1) | 1 (< 1) | 0 | |
| KPS, n (%) | < .001 | |||
| ≥ 90 | 382 (61) | 700 (59) | 231 (57) | |
| < 90 | 214 (34) | 336 (28) | 129 (32) | |
| Missing | 28 (4) | 157 (13) | 46 (11) | |
| Race, n (%) | < .001 | |||
| White | 528 (85) | 1134 (95) | 359 (88) | |
| Black | 38 (6) | 21 (2) | 27 (7) | |
| Asian | 18 (3) | 12 (1) | 5 (1) | |
| Other—American Indian/Native Hawaiian | 23 (4) | 6 (1) | 4 (1) | |
| Missing | 17 (3) | 20 (2) | 11 (3) | |
| AML disease status at transplantation, n (%) | < .001 | |||
| Primary induction failure | 91 (15) | 204 (17) | 65 (16) | |
| CR1 | 337 (54) | 547 (46) | 150 (37) | |
| CR2 | 97 (16) | 261 (22) | 109 (27) | |
| First relapse | 80 (13) | 173 (15) | 79 (19) | |
| Missing | 19 (3) | 8 (1) | 3 (1) | |
| Cytogenetics, n (%) | < .001 | |||
| Unknown | 29 (5) | 75 (6) | 31 (8) | |
| Normal | 288 (46) | 403 (34) | 127 (31) | |
| Good | 34 (5) | 80 (7) | 27 (7) | |
| Intermediate | 88 (14) | 134 (11) | 56 (14) | |
| Poor | 158 (25) | 394 (33) | 135 (33) | |
| Tested–not evaluated metaphases | 10 (2) | 46 (4) | 7 (2) | |
| Not tested | 17 (3) | 61 (5) | 23 (6) | |
| WBC count at diagnosis, n (%) | .30 | |||
| < 7.6 × 109/L | 258 (41) | 550 (46) | 180 (44) | |
| > 7.6 × 109/L | 296 (47) | 515 (43) | 175 (43) | |
| Missing | 70 (11) | 128 (11) | 51 (13) | |
| Therapy-related AML, n (%) | < .001 | |||
| No | 572 (92) | 1121 (94) | 378 (93) | |
| Yes | 35 (6) | 72 (6) | 25 (6) | |
| Missing | 17 (3) | 0 | 3 (1) | |
| Preexisting MDS, n (%) | < .001 | |||
| No | 426 (68) | 879 (74) | 309 (76) | |
| Yes | 130 (21) | 313 (26) | 95 (23) | |
| Missing | 68 (11) | 1 (< 1) | 2 (< 1) | |
| Extramedullary disease, n (%) | < .001 | |||
| No | 570 (91) | 1122 (94) | 387 (95) | |
| Yes | 39 (6) | 68 (6) | 16 (4) | |
| Missing | 15 (2) | 3 (< 1) | 3 (1) | |
| Median interval between diagnosis and transplantation, mo (range) | 5 (1-142) | 6 (1-133) | 7 (1-114) | |
| Median interval from CR1 to transplantation for patients transplanted in CR1, mo (range) | 3 (1-25) | 3 (1-24) | 4 (1-14) | |
| Median CR1 duration (only patients transplanted in CR2), mo (range) | 10 (1-53) | 11 (1-110) | 11 (1-100) | |
| Median donor age, y (range) | 50 (7-85) | 34 (19-61) | 37 (19-60) | < .001‡ |
| Donor age group, y, n (%) | < .001 | |||
| < 20 | 16 (3) | 14 (1) | 2 (< 1) | |
| 20-29 | 35 (6) | 406 (34) | 92 (23) | |
| 30-39 | 75 (12) | 427 (36) | 158 (39) | |
| 40-49 | 180 (29) | 273 (23) | 118 (29) | |
| 50-59 | 180 (29) | 71 (6) | 35 (9) | |
| > 60 | 131 (21) | 2 (< 1) | 0 | |
| Missing | 7 (1) | 0 | 1 (< 1) | |
| Sex match, n (%) | < .001 | |||
| M/M | 200 (32) | 436 (37) | 146 (36) | |
| M/F | 132 (21) | 369 (31) | 99 (24) | |
| F/M | 155 (25) | 182 (15) | 80 (20) | |
| F/F | 132 (21) | 205 (17) | 81 (20) | |
| Missing | 5 (1) | 1 (< 1) | 0 | |
| CMV match, n (%) | < .001 | |||
| +/+ | 258 (41) | 202 (17) | 96 (24) | |
| +/− | 71 (11) | 86 (7) | 37 (9) | |
| −/+ | 146 (23) | 499 (42) | 136 (33) | |
| −/− | 130 (21) | 325 (27) | 104 (26) | |
| Not tested/inconclusive | 19 (3) | 81 (7) | 33 (8) | |
| Conditioning regimen intensity, n (%) | .003 | |||
| Traditional ablative | 335 (54) | 547 (46) | 220 (54) | |
| Reduced intensity | 135 (22) | 336 (28) | 104 (26) | |
| Nonmyeloablative | 74 (12) | 148 (12) | 36 (9) | |
| Nontraditional ablative† | 80 (13) | 162 (14) | 45 (11) | |
| Missing | 0 | 0 | 1 (< 1) | |
| Stem cell source, n (%) | < .001 | |||
| BM | 48 (8) | 328 (27) | 105 (26) | |
| Peripheral blood | 576 (92) | 865 (73) | 301 (74) | |
| GVHD prophylaxis, n (%) | < .001 | |||
| Missing | 3 (< 1) | 0 | 0 | |
| None | 14 (2) | 8 (1) | 4 (1) | |
| FK506 + MTX + other | 241 (39) | 578 (48) | 191 (47) | |
| FK506 + other | 104 (17) | 249 (21) | 79 (19) | |
| CsA + MTX + other | 124 (20) | 192 (16) | 87 (21) | |
| CsA + other | 125 (20) | 149 (12) | 39 (10) | |
| Other | 13 (2) | 17 (1) | 6 (1) | |
| Antithymocyte globulin, n (%) | < .001 | |||
| No | 565 (91) | 894 (75) | 306 (75) | |
| Yes | 59 (9) | 299 (25) | 100 (25) | |
| Year of transplantation, n (%) | ||||
| 2002 | 99 (16) | 124 (10) | 38 (9) | |
| 2003 | 89 (14) | 166 (14) | 69 (17) | |
| 2004 | 141 (23) | 275 (23) | 89 (22) | |
| 2005 | 157 (25) | 295 (25) | 106 (26) | |
| 2006 | 138 (22) | 333 (28) | 104 (26) | |
| Median follow-up of survivors, mo (range) | 57 (2-97) | 42 (6-89) | 45 (3-85) | |
| Total deaths, n | 397 | 773 | 275 |